ASH 2023 | The addition of acalabrutinib to lenalidomide and rituximab in patients with treatment-naïve FL
Paolo Strati, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the findings of a Phase II study which investigated the addition of acalabrutinib to lenalidomide and rituximab in patients with previously untreated follicular lymphoma (FL). High complete response rates were achieved early in treatment with this combination therapy, and acalabrutinib was found to affect the phenotype of circulating monocytes and tumor-associated macrophages. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Board of Directors/Advisory Committee: Astrazeneca Acerta, Kite Gilead, Sobi, ADC Therapeutics
Research Funding: Astrazeneca Acerta, ALX Oncology, Kite Gilead, Sobi, ADC Therapeutics
Consultancy: Roche Genentech, Hutchinson MedoPharma
